Tacrine, and Alzheimer's treatments

Journal of Alzheimer's Disease

Volumn 9, Issue SUPPL. 3, 2006, Pages 439-445

  Summers, William K ^a  

^a ALZcorp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; TAU PROTEIN; THIORIDAZINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DELIRIUM; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SENILE DEMENTIA; TREATMENT OUTCOME;

EID: 84880186810     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2006-9s350     Document Type: Review

References (49)

1. A. Albert, The acridines; their preparation, physical, chemical, and biological properties and uses, Edward Arnold & Co., London, 1951.
2. M.S. Albin, L. Bunegin, Massopust and P.J. Jannetta, Ketamine-induced postanesthetic delirium attenuated by tetrahydroaminoacridine, Exp Neurol 44(1) (1974), 126-129. and personal communications.
3. Art Gherkin died in 1990 before his work really became well known. Art Kling died in 1998 in time to see much of his years of effort come to fruition. Ken Tachiki, my friend the dreamer, died in December, 2004. Robert Bartley, distinguished editor of The Wall Street Journal died in 2004. All are much missed.
4. R.N. Butler, Mission of the National Institute on Aging, J Am Geriatr Soc 25(3) (1977), 97-103.
5. P. Davies and A.J. Maloney, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet 2 (1976), 1403.
6. K.L. Davis, L.J. Thal, E.R. Gamzu, C.S. Davis, R.F. Woolson, S.I. Gracon, D.A. Drachman, L.W.S. Schneider, P.J. Whitehouse, T.M. Hoover, J.C. Morris, C.H. Kawas, D.S. Knopman, N.L. Earl, V. Kumar and R.S. Doody, A double-blind placebo controlled multicenter study of tacrine for Alzheimer's disease. The tacrine collaborative study group, N Engl J Med 327 (1992), 1253-1259.
7. I.S. De La Lande and G.A. Bentley, The action of morphine and antagonists of the narcotic action of morphine on acetylcholine synthesis in brain, Aust J Exp Biol Med Sci 33 (1955), 55-559.
8. J.A. DiMasi, R.W. Hansen and H.G. Grabowski, Assessing claims about the cost of new drug development: a critique of the Public Citizen and Tuberculosis Alliance reports. Tufts Center for the Study of Drug Development, Tufts University, November 1, 2004.
9. Editorial. Dr. Summer's Victory. WSJ 25 May 1989; A16.
10. M. Farlow, S.I. Gracon, L.A. Hershey, K.W. Lewis, C.H. Sandowsky and J. Dolan-Ureno, A controlled trial of tacrine in Alzheimer's disease: the tacrine study group, JAMA 268 (1992), 2523-2529.
11. S. Gershon, Behavioral effects of anticholinergic psychotomimetics and their antagonists in man and animals, Rec Adv Biol Psychiat 13 (1966), 151.
12. R.P. Granacher and R. Baldessarini, Physostigmine - its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs, Arch Gen Psychiat 32 (1975), 375-380.
13. C. Haass and D. Selkoe, Alzheimer's disease. A technical KO of amyloid-beta peptide, Nature 391 (22 Jan 1998), 339-340.
14. G. Irving, R.A. Robinson and W. McAdam, The validity of some cognitive tests in the diagnosis of dementia, Brit J Psychiatry 117 (1970), 149-156.
15. P.N. Kaul, Enzyme inhibiting action of tetrahydroaminoacridine and its structural fragments, J Pharm Pharmacol 14 (1962), 243-245.
16. A. Kling, L.J. Fitten, K. Perryman and K. Tachiki, Oral Tacrine Administration in Middle Aged Monkeys: Effect on Discrimination Learning, Soc for Neurosci Annual Meeting (20 October 1985), abstract No. 114.7.
17. M.J. Knapp, D.S. Knopman, P.R. Solomon, W.W. Pendlebury, C.S. Davis and S.I. Gracon, A thirty week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: the tacrine study group, JAMA 271 (1994), 985-991.
18. S.E. Lind, Fee-for-service research, N Engl J Med 314 (1986), 312-315.
19. M.E. Obrenovich, J.A. Joseph, C.S. Atwood, G. Perry and M.A. Smith, Amyloid-beta: a (life) preserver for the brain, Neurobiology of Aging 23 (2002), 1096-1099.
20. T.H. Park, K.H. Tachiki, W.K. Summers, D. Kling, J. Fitten, K. Perryman, K. Spidel and A.S. Kling, Isolation and the fluorometric high-performance liquid chromatographic determination of tacrine, Anal Biochem 159 (1986), 358-362.
21. E.K. Perry, B.E. Tomlinson, G. Blessed, K. Bergmann, P.H. Gibson and H.R. Perry, Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia, Brit Med J ii (1978), 1457-1459.
22. D. Pressman, Patent It Yourself, (1st ed.), Nolo Press: Berkeley, CA, 1985.
23. A. Rashti, S. Childers, K. Tachiki, C. Melchior, A. Steinberg and R.F. Ritzmann, Alterations in response to ethanol by tacrine and physostigmine, Soc Neurosci (1988), Abstract 14.
24. C.A. Rottkamp, A.K. Raina, X. Zhu, E. Gaieve, A. Bush, C.S. Atwood, M. Chevion, G. Perry and M.A. Smith, Redox active iron mediated amyloid beta toxicity, Free Radical Biology and Medicine 30 (2001), 447-450.
25. J. Scott, Alzheimer prober partly vindicated by UCLA panel, Los Angeles Times (9 Aug 1988), A3.
26. F.H. Shaw and G.A. Bentley, Pharmacology of some anticholinesterases, Aust J Exp Biol Med Sci 31 (1953), 573-576.
27. T. Sjögren, H. Sjögren and A.G.H. Lindgrend, Morbus Alzheimer and morbus pick, Acta Psychiat Neurol Scand 82(Suppl) (1953), 1-152.
28. W.K. Summers, A clinical method of estimating risk of drug induced delirium, Life Sciences 22 (1978), 1511-1516.
29. W.K. Summers, Administration of monoamine acridines in cholinergic neuronal deficit states. United States Patent No. 4,816,456.
30. W.K. Summers, Alzheimer's disease, oxidative injury, and cytokines, J Alz Dis 6 (2004), 651-657.
31. W.K. Summers, Fee-for-service research on THA: an explanation, N Engl J Med 316 (1987), 1605-1606.
32. W.K. Summers, Tacrine (THA, Cognex®), J Alzheimer's Dis 2 (2000), 85-93.
33. W.K. Summers, Psychiatric sequellae to cardiotomy, J Cardiovascular Surg 20 (1979), 471-476.
34. W.K. Summers, R.E. Allen and F.N. Pitts, Does physostigmine reverse quinidine delirium? West J Med 135 (1981), 411-414.
35. W.K. Summers, V.L. DeBoynton, G.M. Marsh and L.J. Majovski, Comparison of seven psychometric instruments used for evaluation of treatment effect in Alzheimer's disease, Neuroepidemiology 9 (1990), 193-207.
36. W.K. Summers, K.R. Kaufman, F. Altman and J.M. Fischer, THA-A review of the literature and its use in treatment of five overdose patients, Clin Toxicol 16 (1980), 269-281.
37. W.K. Summers, L.V. Majovski, G.M. Marsh, K. Tachiki and A. Kling, Oral Tetrahydroaminoacridine in Long-term Treatment of Senile Dementia, Alzheimer Type, N Engl J Med 315 (1986), 1241-1245.
38. W.K. Summers, L.V. Majovski, G.M. Marsh, K.H. Tachiki and A. Kling, Oral tetrahydroamino acridine in the treatment of senile dementia Alzheimer's type: Response to six letters to the Editor, N Engl J Med 316 (1987), 1603-1605.
39. W.K. Summers and T.C. Reich, Delirium after cataract surgery: review and two cases, Am J Psychiat 136 (1979), 386-391.
40. W.K. Summers, E. Robins and T.C. Reich, The natural history of acute organic mental syndrome after bilateral electroconvulsive therapy, Biological Psychiatry 14 (1979), 905-912.
41. W.K. Summers, K.H. Tachiki and A. Kling, Tacrine in the treatment of Alzheimer's disease, Euro Neurol 29(suppl 3) (1989), 28-32.
42. W.K. Summers, J.O. Viesselman and L. Bivens, Gerontology Symposium: Practical Issues for Family Practice, Neurology, and Psychiatry, Bonaventure Hotel, Los Angeles, CA, April 8-10, 1981.
43. W.K. Summers, J.O. Viesselman, G.M. Marsh and K. Candelora, Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients, Biol Psychiat 16 (1981), 145-153.
44. Y. Tatebayashi, T. Miyasaka, D.H. Chui, T. Akagi, K. Mishima, K. Iwasaki, M. Fujiwara, K. Tanemura, M. Murayama, K. Ishiguro, E. Planel, S. Sato, T. Hashikawa and A. Takashimaya, Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau, Proc Natl Acad Sci USA 99(21) (15 Oct 2002), 13896-13901.
45. R.D. Terry, Dementia. A brief and selective review, Arch Neurol 33(1) (1976), 1-4.
46. M. Waldholz, A psychiatrist's work leads to a US study of Alzheimer's drug, WSJ (4 Aug 1987), pA1.
47. M. Waldholz, FDA approves sale of Cognex for Alzheimer's, WSJ (10 Sep 1993), B5.
48. G.K. Wilcock, D.J. Surmon, M. Scott. M. Boyle, K. Mulligan and K.A. Heubauer, An evaluation of efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease, Age Ageing 22 (1993), 316-324.
49. R. Winslow, Weighing the risks and benefits in the drug-safety debate, WSJ (16 Feb 2005), B1-B2.